October 9, 2015
The 8thUniferon
Global Anaemia Summit was held in Berlin, Germany from September
9-11, 2015.
A global delegation of leading swine producers, veterinarians and
industry consultants representing more than 20 countries
participated in this year's summit.
The purpose of this year's summit was to create
awareness about the iron status in the herd as an indicator for
performance, where a herds iron status may be determined by the
hemoglobin level.
The international Iron Expert Board (IEB) presented their
latest findings and an introduction to The F.A.C.T
Calculator, a
tool for optimizing a herds production potential, was
given.
Lectures from guest speakers covered topics
such as learnings from on-site anaemia
investigations and Porcine Epidemic
Diarrhea.
The outcome of each Summit is that the swine industry
learns more about accurate pen-side anaemia detection and treatment
protocols that help improve the producer's return on
investment.
We would like to thank all the participants for their
valuable contribution making the 8th Uniferon Global
Anaemia Summit a huge success.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.